Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM608 in Mild to Moderate Parkinson's Disease
NCT01850381Phase 2Completed
- Sponsor
- Genervon Biopharmaceuticals
- Start
- Jun 2013
- Primary completion
- Jul 2014
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of alirinetide in Parkinson's disease (PD), sponsored by Genervon Biopharmaceuticals. Primary endpoints: Change from the mean total UPDRS score of the combined screening and baseline visits to the total UPDRS score at the Week-12 visit and Compare safety and tolerability with placebo at 12 weeks. Started Jun 2013; status: completed.
02
Drugs
alirinetide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01850381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01850381.